Effect of recombinant human growth hormone on exercise capacity in patients with HIV-associated wasting on HAART

Published

Journal Article

Over 700 patients with HIV-associated wasting while receiving HAART were randomly assigned to double-blind treatment for 12 weeks with recombinant human growth hormone (rhGH) daily or on alternate days, or to placebo. Maximum exercise intensity increased by a median of 2.35 kJ in the alternate-days group and 2.60 kJ in the daily group but decreased by 0.25 kJ in the placebo group. The median difference between the daily and placebo groups was 2.85 kJ (P < .0001). These improvements suggest that rhGH treatment may enable patients with wasting to perform activities of daily living that would be exhausting without rhGH treatment.

Duke Authors

Cited Authors

  • Evans, WJ; Kotler, DP; Staszewski, S; Griffin, GE; Isgaard, J; Gertner, JM; O'Brien, F; Svanberg, E

Published Date

  • January 1, 2005

Published In

Volume / Issue

  • 15 / 6

International Standard Serial Number (ISSN)

  • 1053-0894

Citation Source

  • Scopus